The compounds with reported activity included flavonoids, phenolic compounds, triterpenoids, alkaloids, polysaccharides, and plant extracts, but the strength and specificity of the evidence varied substantially among them. PPARγ is a ligand-dependent nuclear receptor encoded by the PPARG gene. It is expressed in colonic epithelial cells and in macrophages, dendritic cells, T lymphocytes, and other cell types.

Ligand binding changes the receptor’s conformation, allowing it to form a complex with retinoid X receptor, bind PPAR response elements, and recruit transcriptional co-regulators. PPARγ can also restrain inflammatory transcriptional programs involving NF-κB, AP-1, and STAT. The review presents reduced expression or impaired activity of PPARγ as a possible link among persistent inflammation, altered immune-cell behavior, disturbed microbial ecology, and damaged mucosal barriers.

In that framework, PPARγ is a regulatory hub linking several interdependent processes rather than a target isolated to one inflammatory pathway. One proposed function of PPARγ is to limit inflammatory amplification. Experimental activation in colitis models reduced sustained NF-κB signaling and expression of mediators including TNF-α, IL-1β, IL-6, and inducible nitric oxide synthase.

The receptor is also associated with adaptive immune balance: experimental findings indicate that PPARγ can suppress the RORγt-associated Th17 program while supporting Foxp3, TGF-β, IL-10, and the regulatory T-cell phenotype. In macrophage models, PPARγ-related signaling was linked to reduced M1-like activation and increased markers associated with the M2-like phenotype, including CD206 and arginase-1. These observations describe relationships in experimental systems; they do not show that restoring PPARγ alone would reverse established human disease.

The proposed effects of PPARγ extend into metabolism and the intestinal ecosystem. Reduced receptor activity may alter epithelial oxidative metabolism, oxygen availability, and nitrate levels, creating conditions that favor facultative anaerobic bacteria such as Enterobacteriaceae. The relationship also runs in the opposite direction.

Short-chain fatty acids, including butyrate, propionate, and acetate, are associated with epithelial metabolism, barrier function, and PPARγ-related signaling, whereas the microbiota-derived metabolite imidazole propionate was reported to inhibit PPARγ. These findings suggest a reciprocal microbiota-metabolite-receptor network, but they remain preclinical. Many studies measured selected microbes, metabolites, or pathway markers rather than the full microbial ecology associated with human ulcerative colitis.

The mucosal barrier is another major focus of the evidence. PPARγ signaling has been linked with MUC2-producing goblet cells, mucin secretion, and the expression and membrane localization of tight-junction proteins such as ZO-1, occludin, and claudins. In the reviewed experiments, compounds including paeonol, ginsenoside Rb1, geniposide, magnolol, and several plant extracts were associated with improvements in some barrier markers, inflammatory measures, or histological injury.

The pattern was not uniform: individual studies used different models, doses, endpoints, and combinations of assays. A compound that increased PPARγ expression or reduced downstream inflammatory markers was therefore not necessarily shown to bind the receptor directly, and improvement in one experimental system did not establish efficacy in people with ulcerative colitis. The strength of the proposed mechanism depends on how PPARγ was tested.

The review grouped evidence into altered receptor expression, molecular docking predictions, pharmacological blockade or rescue, direct binding and transcriptional assays, and genetic evaluation. These categories are not interchangeable. Increased PPARγ abundance may be a downstream consequence of reduced inflammation, while sensitivity to a PPARγ antagonist indicates that the receptor contributes to a measured effect but does not by itself demonstrate that a compound binds it.

That evidence nevertheless remained preclinical and was based mainly on an acute chemically induced model. Several studies used GW9662 or T0070907 as PPARγ antagonists to assess functional involvement. Loss of protection after receptor blockade can strengthen causal inference, but it has limits.

Pharmacological antagonism may have different effects from genetic deletion, and a compound may influence several pathways that converge on PPARγ without binding the receptor. Accordingly, results from emodin, paeonol, honokiol, naringin, and several extracts support PPARγ-dependent components of their effects but do not establish direct molecular targeting. Molecular docking also requires caution.

Predicted contacts with residues in the PPARγ ligand-binding domain constitute a computational hypothesis, not evidence of physical binding. Polyphenols, flavonoids, and quinones may also aggregate, chelate metals, participate in redox reactions, or interfere nonspecifically with assay components. The review cautions that structural alerts associated with PAINS compounds do not automatically make their pharmacology false, but they increase the need for rigorous follow-up.

Orthogonal experiments using different detection principles, reverse screens for aggregation and redox interference, direct binding assays, receptor transcriptional-activity tests, and genetic interventions could build a stronger evidence chain. For complex plant extracts, chemical characterization, activity-guided isolation, and back-filling experiments would also be needed to identify which constituents or combinations account for the observed activity. The relevant biological context is also unresolved because whole-colon measurements combine epithelial cells, macrophages, dendritic cells, and T lymphocytes, which can have different transcriptional programs.

Cell-specific knockouts and spatially resolved analyses could clarify which cell populations account for a compound’s effects. Disease-model design and exposure are additional limits on interpretation. Many experiments used acute dextran sulfate sodium exposure, which induces epithelial injury and inflammation but does not fully reproduce the chronic, relapsing, immunologically heterogeneous course of human ulcerative colitis.

The review recommends adding chronic or recurrent designs, trinitrobenzene sulfonate and T-cell adoptive-transfer models, and patient-derived colonic organoids. Microbiome results also require tests of direction: changes in community composition or metabolites accompanying improvement do not show that microbial remodeling caused the response. Germ-free animals, antibiotics, metabolite supplementation, and targeted pathway manipulation could help distinguish direct receptor effects from changes in epithelial metabolism or microbial composition.

Translation also requires measuring parent compounds and active metabolites in plasma, colonic tissue, and intestinal contents, because a concentration active in cultured cells may not be attainable after oral dosing. Repeated-dose toxicology and assessments of systemic metabolic effects are needed because PPARγ participates in adipocyte function, lipid storage, insulin sensitivity, and glucose homeostasis. The review’s central conclusion is consequently a research framework, not a clinical recommendation: PPARγ-linked natural compounds may offer multi-target candidates, but target specificity, cell-resolved mechanisms, reproducible exposure, and safety must be established before their therapeutic value in ulcerative colitis can be assessed in humans.

Subject of Research: Preclinical evidence on natural compounds modulating PPARγ-related signaling in ulcerative colitis models

Article Title: PPARγ signaling pathway: strategies and limitations of natural compounds in the treatment of ulcerative colitis

Article References: Liang, L., & Deng, H. (2026). PPARγ signaling pathway: strategies and limitations of natural compounds in the treatment of ulcerative colitis. Frontiers in Pharmacology, 17, Article 1977683. https://doi.org/10.3389/fphar.2026.1977683

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1977683

Keywords: ulcerative colitis, PPARγ, natural compounds, preclinical research, animal models, cellular models, gut microbiota, mucosal barrier, inflammation, clinical translation, PPAR, signaling

The study screened a library of phytochemicals selected for their reported potential to inhibit resistance enzymes rather than for direct antimicrobial activity. The researchers used ADMET profiling, or assessment of absorption, distribution, metabolism, excretion and toxicity, followed by molecular docking against the NDM-1 and KPC-2 β-lactamase enzymes. Quercetin, eriodictyol and luteolin produced favorable predicted docking scores: −9.1, −8.32 and −8.66 kcal/mol against KPC-2, and −8.74, −8.72 and −8.73 kcal/mol against NDM-1, respectively.

Molecular dynamics simulations were then performed for quercetin complexes with NDM-1 and KPC-2 to examine the predicted conformational behavior of those complexes. These computational findings supported further investigation of quercetin, but the docking and simulation results were predictions rather than direct measurements of enzyme inhibition. The reported in vitro assay showed potentiation of carbapenem activity against the CRKP isolate, while the abstract states that the assays did not directly assess β-lactamase inhibition.

The findings therefore identify quercetin as a preliminary carbapenem-adjuvant candidate under laboratory conditions, with supporting computational analyses and an observed improvement in antibacterial activity. The mechanism responsible for that potentiation remains unconfirmed, and the supplied evidence does not establish whether quercetin directly inhibits NDM-1, KPC-2 or another target. The results are also limited in scope because the reported laboratory testing involved one CRKP isolate; the abstract does not provide evidence about activity against a broader isolate collection or clinical effectiveness in people. The article was published on 12 October 2026 as an open-access, early version of peer-reviewed research and was described as subject to further edits before replacement by the final version of record.

Subject of Research: In vitro and computational evaluation of quercetin as a potential carbapenem adjuvant against a carbapenem-resistant Klebsiella pneumoniae isolate

Article Title: Phytochemical screening as an inhibitor of β-lactamases to overcome the carbapenem-resistant of Klebsiella pneumoniae

Article References: Azmal, M., Paul, J. K., Shohan, M. N. H., Haque, A. N. M. S. N. B., Mrinmoy, M., Talukder, O. F., Mishu, M. A., Mia, M. W., & Ghosh, A. (2026). Phytochemical screening as an inhibitor of β-lactamases to overcome the carbapenem-resistant of Klebsiella pneumoniae. Scientific Reports. https://doi.org/10.1038/s41598-026-68970-0

Image Credits: AI Generated

DOI: 10.1038/s41598-026-68970-0

Keywords: quercetin, Klebsiella pneumoniae, carbapenem resistance, β-lactamases, NDM-1, KPC-2, molecular docking, ADMET profiling, in vitro assay, Scientific Reports, Phytochemical, screening

The review, authored by R. Mikal Lange and Tasneem P. Sharma of Indiana University School of Medicine, takes stock of why SANS has proven so stubborn. On Earth, hydrostatic pressure gradients push one to two liters of fluid toward the legs when a person stands upright, keeping intracranial pressure relatively low. In microgravity that gradient disappears, and fluid redistributes toward the head. Contrary to early expectations, lumbar puncture data and ground-based analogues suggest intracranial pressure in orbit is only mildly elevated, but it stays elevated chronically because astronauts cannot assume an upright posture. This persistent mild elevation narrows the translaminar pressure gradient across the lamina cribrosa, the meshwork where the optic nerve exits the eye, which may help drive posterior globe flattening, optic disc edema, and remodeling of the optic nerve head. Optic disc edema is detected in roughly 70 percent of crew members on long missions, appearing as early as flight day 30 and progressing throughout flight.

Mechanical forces are only part of the story. Microgravity also impairs cranial venous outflow: astronauts have shown stagnant retrograde flow in the internal jugular veins, one documented case of in-flight jugular vein thrombosis, and greater increases in dural venous sinus volumes among those who developed SANS. Emerging magnetic resonance imaging evidence points to glymphatic dysfunction as well, with perivascular spaces in white matter and basal ganglia enlarging from preflight to postflight in proportion to SANS severity. Meanwhile, galactic cosmic radiation and microgravity generate a robust oxidative stress response, producing reactive oxygen species that damage DNA, proteins, and lipids, alongside endothelial dysfunction, disrupted nitric oxide signaling, and chronic low-grade inflammation. A recent analysis even suggested that SANS may involve retinal vascular rarefaction rather than the pathological neovascularization seen in wet macular degeneration and diabetic retinopathy. Crucially, the pattern of Bruch’s membrane deformations in SANS differs from idiopathic intracranial hypertension, and one modeling study proposed that anteriorly directed force from orbital fat swelling in microgravity may press on the globe more powerfully than pressure changes alone.

Because no single unifying mechanism has been proven, Lange and Sharma hypothesize that mitigating SANS will require a multimodal approach hitting oxidative, inflammatory, microvascular, and metabolic pathways simultaneously. That is where natural compounds enter the picture. The authors argue that in space, where medical resources are limited and even mild side effects can be consequential, agents with high therapeutic indices are especially attractive. They frame these compounds primarily as prophylactic countermeasures, administered before and during flight to blunt the injury cascades that drive SANS, rather than as cures for established pathology. Their evidence base is drawn from terrestrial eye diseases, chiefly glaucoma, age-related macular degeneration, and diabetic retinopathy, which converge with SANS on the same downstream pathways of oxidative stress, endothelial dysfunction, and inflammation even though the diseases themselves are distinct.

The first candidate, Mirtogenol, combines bilberry anthocyanins with French maritime pine bark extract. Its constituents scavenge reactive oxygen species, upregulate antioxidant enzymes such as superoxide dismutase and glutathione peroxidase, boost nitric oxide production to relax blood vessels, and stabilize leaky retinal capillaries. In a prospective controlled trial of 38 people with elevated intraocular pressure, Mirtogenol lowered pressure from about 25.2 to 22.0 millimeters of mercury over two to three months while improving blood flow in the central retinal, ophthalmic, and posterior ciliary arteries, and a Wistar rat glaucoma model showed reduced retinal ganglion cell apoptosis. The authors stress that the rationale in space is not pressure lowering, since in-flight intraocular pressure rises only about 1.3 millimeters of mercury on average, but rather antioxidant, anti-inflammatory, and vasoprotective effects that could counter venous congestion. Safety data across six months showed no observed adverse effects.

Ginkgo biloba extract, particularly the standardized EGb 761 formulation, offers a complementary profile. Its flavonoids scavenge reactive oxygen and nitrogen species, its terpenoids upregulate reducing enzymes including catalase and heme-oxygenase 1, and the extract improves blood rheology by promoting erythrocyte deformability, raising nitric oxide, and lowering fibrinogen, thereby inhibiting microthrombus formation. Studies in normal-tension glaucoma have yielded mixed results on visual field preservation, with one four-year observational study reporting significant improvement while a four-week randomized crossover trial in 28 patients found no benefit. However, human studies consistently show increased ophthalmic artery and retrobulbar blood flow velocities, and rodent work demonstrates increased choroidal blood flow. Systematic reviews found no significant difference in adverse events versus placebo across 80 to 600 milligrams daily, though one review flagged a possible association with bleeding risk that a 50-volunteer coagulation study failed to confirm.

Saffron and its constituents crocin and crocetin bring a different mechanism: activation of the NRF2 transcription factor, which switches on endogenous antioxidant genes, plus suppression of the pro-inflammatory NF-κB pathway and demonstrated enhancement of oxygen diffusion and ocular blood flow in animal studies. In clinical trials, saffron preserved visual acuity and retinal flicker sensitivity in age-related macular degeneration, lowered intraocular pressure as an adjunct to timolol and dorzolamide in a pilot glaucoma study, and improved central macular thickness, visual acuity, and HbA1c in diabetic maculopathy at 15 milligrams daily. Doses under 1.5 grams per day show no excess adverse events, and therapeutic ocular doses run 15 to 50 milligrams daily, giving the spice a high therapeutic index. Curcumin, the turmeric-derived polyphenol, scavenges free radicals, blocks NF-κB, induces heme oxygenase-1, and restored mitochondrial function in a rodent ischemia-reperfusion glaucoma model. Yet the authors caution a critical caveat: curcumin and resveratrol are both anti-angiogenic, and since SANS may involve retinal vascular rarefaction, dampening new vessel growth could theoretically backfire.

The remaining candidates round out four overlapping mechanistic domains. Coenzyme Q10 sits at the heart of the mitochondrial electron transport chain and acts as a potent antioxidant; in a 106-patient trial, a regimen including 30 milligrams daily improved visual field mean defect and foveal sensitivity in macular degeneration, and glaucomatous mice given CoQ10 showed greater retinal ganglion cell survival. Resveratrol upregulates NRF2 and HO-1 antioxidant pathways and suppresses NF-κB, reducing TNF-α, IL-1β, and IL-6, with observational data in wet macular degeneration showing fewer anti-VEGF injections over 24 months. Vitamin E isoforms have demonstrated radioprotective properties, shielding mouse bone marrow and human CD34+ cells from radiation damage, which is directly relevant to cosmic ray exposure, though the NIH tolerable upper limit of 1,000 milligrams daily must be respected to avoid bleeding complications. B vitamins occupy a uniquely SANS-specific niche: astronauts with detectable SANS showed 25 to 45 percent higher serum homocysteine, cystathionine, and methylmalonic acid, and polymorphisms in the one-carbon metabolism genes MTRR and SHMT1 have been linked to chorioretinal folds and optic disc edema, with B-vitamin status predicting ocular outcomes.

The authors are careful to underline how preliminary all of this remains. No spaceflight or analogue studies of these compounds have been conducted, and a single documented in-flight case, in which an astronaut with two genetic risk factors received B6, methylfolate, B12, and riboflavin from flight day 153, showed improvement but was confounded by natural disease course and a simultaneous reduction in cabin carbon dioxide. Practical hurdles also loom: pharmaceuticals degrade faster in space due to radiation, humidity swings, and vibration, so any countermeasure must survive a multi-year Mars mission without resupply, and altered pharmacokinetics in microgravity could change how supplements are absorbed and cleared. To move forward, the review proposes two testable hypotheses: that pre- and in-flight supplementation with an antioxidant or vasoregulatory compound reduces optic disc edema and choroidal thickening, and that combining metabolic supplementation with mechanical countermeasures such as lower body negative pressure yields additive protection. Head-down tilt bed rest, supine bed rest, and rodent unloading models that reproduce retinal nerve fiber changes now offer tractable platforms to put kitchen-sack pharmacology to the test before the first crew leaves for the Red Planet.

Subject of Research: Natural compounds as potential countermeasures for spaceflight-associated neuro-ocular syndrome

Article Title: Natural compounds as potential countermeasures for spaceflight-associated neuro-ocular syndrome

Article References: Lange, R. M., & Sharma, T. P. (2026). Natural compounds as potential countermeasures for spaceflight-associated neuro-ocular syndrome. Frontiers in Ophthalmology, 6, Article 1801651. https://doi.org/10.3389/fopht.2026.1801651

Image Credits: AI Generated

DOI: 10.3389/fopht.2026.1801651

Keywords: spaceflight-associated neuro-ocular syndrome, SANS, microgravity, oxidative stress, astronaut vision, natural compounds, Mirtogenol, Ginkgo biloba, saffron, curcumin, coenzyme Q10, B vitamins

The paper, authored by Manyata Srivastava, Shishir Singh, Diksha Ameta, Aesha Singh, Monisha Banerjee and Atar Singh Kushwah, proposes what the team calls the Immunogenicity Control Axis, or ICA. The central idea is deceptively simple: a tumor’s visibility to the immune system is an emergent property that arises only when three molecular layers are coordinated. Epigenetic regulation determines whether immune-relevant genes can be transcribed at all, DNA damage response pathways shape the mutational substrate from which neoantigens are generated, and the immune axis reflects the downstream cytolytic and interferon-driven state that results. Break the chain at any layer, the framework predicts, and even an antigen-laden tumor can remain immunologically invisible.

The epigenetic layer is the framework’s upstream boundary condition. Histone deacetylases and DNA methyltransferases control chromatin accessibility at promoters and enhancers governing MHC class I and II antigen presentation and interferon-responsive signaling. A repressive chromatin state can silence these programs entirely, which means a tumor may harbor abundant immunogenic mutations yet never display the resulting peptides to cytotoxic T cells. The authors point to converging evidence, including studies showing that epigenetic therapy can reverse immune evasion in lung cancer, that chromatin accessibility precedes transcriptional activation of immune genes, making it a plausible causal starting point rather than a mere correlate.

The DNA damage response axis supplies the raw material. Double-strand breaks can be repaired through homologous recombination, classical non-homologous end joining or alternative end joining, and the balance among these pathways differs in fidelity and genomic consequence. The team hypothesizes that repair-pathway configuration contributes to variation in the genomic substrate available for immune recognition, with error-prone end-joining potentially generating distinct spectra of candidate neoantigens. Crucially, the authors are careful not to overclaim: they treat relationships between expression-defined repair states and mutational signatures such as SBS3, linked to homologous-recombination deficiency, and the APOBEC-associated SBS2 and SBS13 signatures, prominent in cervical cancer, as exploratory associations rather than evidence that a specific repair pathway directly forges any particular immunogenic phenotype.

What elevates the paper above a purely conceptual essay is its insistence on quantitative falsifiability. Each axis is operationalized as a standardized score derived from single-sample gene-set enrichment analysis of prespecified transcriptional programs: permissive chromatin and antigen-presentation features contribute positively to the Epigenetic score, the DDR score captures the relative transcriptional shift toward end-joining versus homologous-recombination programs, and the Immune score aggregates cytolytic activity, checkpoint expression and interferon signatures. The composite ICA Score is then computed as the arithmetic mean of the three standardized components, an equal-weight formulation the authors describe deliberately as a transparent, outcome-independent reference model rather than a claim that the three biological systems contribute equally.

Cervical cancer serves as the initial testing ground, and for good reason. HPV-driven tumors coexist with viral antigens that should provoke immune recognition, yet many remain immunologically cold, a paradox the ICA framework attributes to upstream constraints: epigenetic repression can mute antigen presentation despite antigen availability, while repair-pathway bias may yield suboptimal mutation profiles. Using 304 evaluable TCGA-CESC cases, the team dichotomized patients by median ICA Score and found no statistically significant difference in overall survival between high- and low-scoring groups, a negative result they report transparently as exploratory benchmarking rather than validation. In a separate three-year survival classification analysis, however, the ICA composite model achieved an internally cross-validated AUC of 0.931, outperforming TMB plus PD-L1 (0.890), TMB alone (0.869) and PD-L1 alone (0.823), although the authors stress these figures represent in-cohort cross-validation, not independent clinical validation.

The framework extends into a perturbational layer that will likely attract the most attention. Differential-expression analysis between ICA-high and ICA-low tumors generates a bidirectional query signature, which the team matched against compound-induced transcriptional profiles in the LINCS L1000 Connectivity Map resource. Natural compounds whose signatures transcriptionally oppose the ICA-associated state, and whose curated targets span multiple ICA dimensions, are ranked as candidate multi-axis perturbators. Compounds such as curcumin and resveratrol, previously associated with modulation of DNMT and HDAC activity, exemplify the class of agents the framework is designed to evaluate, since their multi-target profiles may in principle touch the epigenetic, DDR and immune layers simultaneously rather than acting on a single isolated node.

The authors are unusually explicit about the epistemic status of every component. Consensus clustering of ICA features, UMAP visualizations of molecular states and even a synthetic demonstration matrix of 30 genes across 80 simulated profiles are all labeled as computational proof of principle, not evidence of biological subtypes. Network connectivity between a compound and an ICA protein is prioritization evidence, not target engagement. The roadmap to validation is staged: molecular reproducibility in independent multi-omics cohorts first, systems-level interrogation of inter-axis relationships second, and clinical benchmarking against PD-L1, TMB and clinicopathological variables in treatment-annotated cohorts only at the final stage, with failure at any step triggering refinement rather than reinterpretation.

The limitations are real. The ICA Score’s component axes are transcriptional and methylation-based correlates, not direct measurements of chromatin accessibility, repair-pathway flux or immune-cell function, and bulk transcriptomic deconvolution methods such as EPIC, xCell and MCP-counter infer rather than measure immune infiltration. The framework’s relative weights may need recalibration across tumor types; in low-mutational-burden cancers, mutation-derived antigenicity may matter less, while hematologic malignancies may require fundamentally different formulations. Prospective validation in independent clinical cohorts, particularly those with documented immunotherapy exposure and response endpoints, remains the decisive test.

Still, the conceptual contribution is difficult to dismiss. By proposing that tumor immunogenicity follows a Regulatory Convergence Principle, in which epigenetic accessibility, repair-pathway bias and immune signaling must align for effective immune visibility, the ICA framework reframes immunotherapy resistance as a systems-level regulatory problem rather than a failure of any single biomarker. It offers the field something it badly needs: a falsifiable, computationally tractable model that connects biological hypothesis to quantitative evaluation, and that specifies in advance what evidence would support or refute it. Whether coordinated multi-axis information truly captures what PD-L1 and tumor mutational burden miss, the coming validation cohorts will tell.

Subject of Research: A multi-omics framework integrating epigenetic regulation, DNA damage response and immune state to explain tumor immunogenicity and immunotherapy response variation

Article Title: The immunogenicity control axis: a multi-omics framework for integrating epigenetic, DNA damage response, and immune states in cancer

Article References: Srivastava, M., Singh, S., Ameta, D., Singh, A., Banerjee, M., & Kushwah, A. S. (2026). The immunogenicity control axis: a multi-omics framework for integrating epigenetic, DNA damage response, and immune states in cancer. Frontiers in Genetics, 17, Article 1944709. https://doi.org/10.3389/fgene.2026.1944709

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1944709

Keywords: immunogenicity control axis, tumor immunogenicity, multi-omics, epigenetics, DNA damage response, immune checkpoint blockade, cervical cancer, TCGA, neoantigens, natural compounds, biomarkers, immunotherapy resistance

The study, led by Greice Itamaro Heiden and colleagues at the Federal University of Santa Catarina in Brazil, set out to answer a question that has lingered over years of laboratory work: does gallic acid’s well-documented anticancer activity in cell cultures actually translate into a living organism, where tumors interact with blood vessels, immune cells, and a host of systemic factors that a petri dish cannot replicate? Most previous evidence came from in vitro experiments on epithelial and blood-derived cancer cell lines, including small-cell lung carcinoma, gastric adenocarcinoma, breast adenocarcinoma, promyelocytic leukemia, and glioma cells. Those studies showed that gallic acid can trigger cell death, halt the cell cycle, and interfere with signaling pathways that drive metastasis and angiogenesis. But the compound’s effects on mesenchymal solid tumors in a whole animal, and its safety profile compared head-to-head with a frontline chemotherapy drug, had never been systematically mapped.

To fill that gap, the team turned to the Sarcoma 180 model, a transplantable mouse tumor that grows rapidly and is widely used for initial screening of potential anticancer agents. Fifty adult male Swiss mice received subcutaneous injections of S-180 ascitic cells, prepared at a standardized concentration of two million viable cells per animal after careful counting with Trypan Blue staining and a Neubauer chamber. Twenty-four hours later, the animals were randomly divided into five groups of ten. Three groups received purified gallic acid, at least 97.5 percent pure, by oral gavage once daily for seven consecutive days at doses of 10, 25, or 50 milligrams per kilogram of body weight. A fourth group received the chemotherapy drug 5-fluorouracil at 25 milligrams per kilogram intraperitoneally, while a control group received only the vehicle solution.

When the animals were euthanized on the eighth day and their tumors weighed, the results showed a clear dose-dependent effect. Mice treated with 25 milligrams per kilogram of gallic acid carried tumors weighing 9.38 grams per 100 grams of body weight, compared with 11.49 grams in the untreated control group, translating to a tumor growth inhibition of roughly 17.6 percent. At the highest dose of 50 milligrams per kilogram, tumor weight fell to 7.21 grams per 100 grams of body weight, an inhibition of 33.7 percent that reached high statistical significance. The lowest dose, 10 milligrams per kilogram, produced no significant effect. As expected, 5-fluorouracil remained the more powerful tumor killer, shrinking tumors by nearly 63 percent, but that potency came at a price the natural compound did not pay.

To understand how gallic acid was attacking the tumors, the researchers performed detailed histopathological and immunohistochemical analyses on the excised tissue. Under the microscope, the S-180 tumors displayed the aggressive features typical of this model: solid sheets of neoplastic cells infiltrating skeletal muscle and fat, perineural invasion, extensive coagulative necrosis, and high mitotic activity exceeding four mitoses per ten high-power fields. The tumor cells showed striking heterogeneity, with rhabdoid, epithelioid, spindle-shaped, and even unusual plant-like forms. Necrotic areas were visibly smaller in both the gallic acid and 5-fluorouracil groups, an early hint that both treatments were pushing tumor cells toward death.

The molecular story that emerged from the immunohistochemistry was remarkably coherent. Gallic acid at 50 milligrams per kilogram cut the expression of Ki-67, a nuclear protein that serves as a standard gauge of cell proliferation, from 14.2 percent of positive nuclei in controls to 9.5 percent. At the same time, it dramatically shifted the balance of the Bcl-2 protein family, which acts as the gatekeeper of mitochondrial suicide: the pro-apoptotic protein Bax rose sharply while the anti-apoptotic Bcl-2 fell, and levels of cleaved caspase-3, the executioner enzyme that dismantles the cell from within, increased significantly. Crucially, cleaved caspase-8, the initiator of the so-called extrinsic death receptor pathway, remained unchanged. Together, this pattern points to preferential activation of the intrinsic, or mitochondrial, apoptotic pathway, in which permeabilization of the mitochondrial membrane releases factors that trigger the caspase cascade and condemn the cell to programmed death.

The study also revealed a third strand in gallic acid’s mechanism: suppression of nuclear factor kappa B, or NF-κB, a transcription factor that functions as a master regulator of tumor cell survival, inflammation, and proliferation. In control animals, 38.4 percent of tumor cell nuclei stained positive for NF-κB; after gallic acid treatment, that figure dropped to 14.4 percent. Because NF-κB drives the production of anti-apoptotic proteins and promotes cell-cycle progression, its inhibition dovetails neatly with the observed increase in apoptosis and the decline in proliferation. The finding is consistent with earlier reports that gallic acid interferes with the MAPK/NF-κB pathway, possibly by reducing phosphorylation and acetylation of the p65 subunit, thereby dampening the factor’s transcriptional output. In effect, the compound appears to attack the tumor from multiple directions at once, strangling growth signals while simultaneously opening the doors to mitochondrial self-destruction.

The safety comparison with 5-fluorouracil may prove to be the study’s most consequential contribution. While the chemotherapy drug achieved greater tumor shrinkage, it devastated the animals’ white blood cell counts, dropping total leukocytes to 2.07 thousand per cubic millimeter, a hallmark of myelosuppression, and caused visible atrophy of the spleen’s white pulp, with shrunken follicles and disrupted lymphoid architecture. Gallic acid, by contrast, preserved leukocyte counts entirely. Liver and kidney weights were unchanged across all groups, serum levels of the liver enzymes AST and ALT stayed within normal ranges, and markers of renal function, urea and creatinine, showed no abnormalities. Histological examination confirmed normal liver and kidney architecture in the gallic acid group. The only notable biochemical shift, a lower AST level in the treated animals, likely reflects reduced tumor burden and less associated muscle damage rather than organ toxicity.

The authors are careful to frame these results as preclinical evidence rather than a promise of a new drug. The S-180 model, though fast and convenient, does not capture the full complexity of human malignancies, and the seven-day treatment window represents only an early snapshot of therapeutic potential. The antitumor efficacy of gallic acid, at roughly half that of 5-fluorouracil, would need substantial improvement, perhaps through combination regimens, novel formulations, or optimized dosing, before human trials could be contemplated. Nevertheless, the mechanistic clarity of the findings is striking: a single dietary polyphenol, taken orally, simultaneously suppressed proliferation, silenced a pro-survival transcription factor, and preferentially ignited the mitochondrial apoptotic pathway, all without measurable harm to blood, liver, or kidney. That combination of efficacy and safety is precisely what makes adjuvant candidates attractive, since the ideal partner to conventional chemotherapy would be one that adds tumor-killing power while shielding patients from the immunosuppression that limits standard treatment. As research into plant-derived anticancer compounds accelerates worldwide, gallic acid has now moved from the cell culture dish into the ranks of molecules with credible, mechanism-backed in vivo evidence, and the next chapter of its story will depend on whether that mitochondrial trigger can be pulled hard enough, and safely enough, in the clinic.

Subject of Research: Antitumor activity and safety of orally administered gallic acid in the murine Sarcoma 180 cancer model

Article Title: Antitumor efficacy and safety profile of gallic acid in the murine sarcoma 180 model

Article References: Heiden, G. I., Costa, M. A. D. S., Alfaia Silva, C., Carvalho, F. M. D. A. D., Amaral, R. G., Rivero, E. R. C., Modolo, F., Gondak, R., & de Albuquerque-Júnior, R. L. C. (2026). Antitumor efficacy and safety profile of gallic acid in the murine sarcoma 180 model. Medical Oncology, 43(11), Article 331. https://doi.org/10.1007/s12032-026-03455-8

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03455-8

Keywords: gallic acid, Sarcoma 180, apoptosis, NF-κB, Ki-67, 5-fluorouracil, polyphenols, preclinical study, mitochondrial pathway, myelosuppression, cancer therapy, natural compounds

The retraction notice, published in the same journal, explains that after publication, concerns were raised regarding image irregularities. When the authors were contacted to clarify the issues, they did not respond. In the world of research integrity, that silence is often decisive. Journals typically give authors an opportunity to explain anomalies in their figures, and when those explanations fail to materialize, editors are left with little choice but to retract. The notice is unambiguous: the editors no longer trust the findings, and the scientific record has been corrected accordingly.

The specific concerns are technical but instructive. According to the retraction notice, a panel in Figure 3B of the retracted paper, labeled as an IL-1 beta condition at a concentration of 10 nanograms per milliliter, appears to overlap with a panel in Figure 6C of a separate 2019 article on nasopharyngeal carcinoma published in Cancer Cell International. Strikingly, the same panel also appears to overlap with a panel in Figure 2D of a second, unrelated paper on pancreatic cancer that has itself since been retracted. In plain terms, identical or nearly identical images seem to have been used to represent entirely different experiments in entirely different disease contexts, spanning osteoarthritis, nasopharyngeal cancer, and pancreatic cancer.

This kind of image duplication is one of the most common triggers for retractions in the modern era of research integrity screening. Western blots, microscopy fields, and other gel-based or imaging outputs are supposed to be unique records of individual experiments. When the same image shows up in multiple papers, or in multiple figures within a single paper, it suggests either careless figure assembly or deliberate fabrication. Software tools and vigilant readers now routinely flag such overlaps, and journals have invested heavily in automated screening pipelines that compare figures across vast swaths of the published literature. What once might have slipped through unnoticed for decades can now be detected within months or years of publication.

The retraction also contains a second, more troubling element: a disputed authorship claim. One of the listed authors, Zhiguang Qiao, stated that he did not contribute to the study and did not consent to being listed as an author of the article. The remaining authors, according to the notice, have not responded to correspondence regarding the retraction. Authorship disputes of this kind raise questions that go beyond the integrity of the data itself. Authorship carries professional credit, responsibility, and accountability, and being listed on a paper without consent is a serious matter. Conversely, when a paper is retracted, every listed author shares in the reputational damage, which is precisely why consent and genuine contribution matter so much.

The original study, published on 7 October 2019, had explored a question of real clinical interest. Osteoarthritis is the most common form of arthritis, affecting hundreds of millions of people worldwide, and its hallmark is the slow degeneration of joint cartilage accompanied by chronic inflammation. Current treatments largely manage symptoms with painkillers and anti-inflammatory drugs, but nothing on the market halts or reverses the underlying disease. That gap has fueled intense interest in natural compounds with anti-inflammatory properties, and acteoside has been one of the candidates. Found in plants such as those used in traditional medicine systems, acteoside had been reported in various laboratory studies to modulate inflammatory signaling, and the JAK/STAT pathway, a chain of molecular interactions that transmits signals from the cell surface to the nucleus, is a well-established regulator of immune and inflammatory responses. Drugs targeting this pathway are already approved for conditions including rheumatoid arthritis, so the hypothesis that a plant compound might act similarly in osteoarthritis was scientifically plausible.

Plausible, however, is not the same as demonstrated. The retraction does not merely erase a single data point; it removes the evidentiary basis for the paper’s central claim that acteoside inhibits inflammatory responses via JAK/STAT signaling in osteoarthritic rats. Readers who encounter the paper in databases or citation lists will now find it flagged as retracted, and responsible researchers will exclude it from systematic reviews and meta-analyses. This matters because complementary and alternative medicine research is frequently cited in public discussions of herbal remedies, and retracted findings can linger in the popular imagination long after the formal correction. A retraction notice is a small document, but its function is to stop the spread of unreliable conclusions before they harden into accepted wisdom.

The case also illustrates the interconnected nature of research integrity problems. The two articles whose figures allegedly overlap with the retracted osteoarthritis paper are themselves notable: one, on circular RNA in nasopharyngeal carcinoma, remains in the literature as far as the notice indicates, while the other, a study of solasodine against pancreatic cancer, is explicitly labeled as retracted. When the same images surface across papers from what appear to be different research groups or different disease areas, integrity investigators often look for common threads, such as shared figure-preparation services, paper mills, or overlapping authorship networks. The retraction notice itself does not draw such conclusions, and it would be wrong to speculate beyond what the editors have stated. But the pattern of a single panel appearing in three different disease contexts is exactly the kind of red flag that has, in other cases, led to much larger sweeps of retractions.

For the journal, BMC Complementary Medicine and Therapies, the retraction is part of a broader reckoning. Journals in the complementary medicine space have faced particular scrutiny in recent years, in part because the field attracts a high volume of submissions and in part because several journals in adjacent areas experienced mass retractions linked to paper mills. Editors have responded with stricter checks at submission, including image forensics, statistical scrutiny, and requirements for raw data. The fact that this retraction was issued years after the original publication, and that the notice was published in 2026 with a new article number and DOI, reflects the often slow but methodical pace of post-publication correction. Investigations take time, correspondence with authors can drag on for months, and legal considerations sometimes complicate matters further.

What should readers take away from this episode? First, that the self-correcting machinery of science, however slow, does function. A paper published in 2019 has been formally retracted, its problems documented, and its authors given the chance to respond. Second, that images are evidence. The figures in a scientific paper are not illustrations; they are the data themselves, and their integrity is inseparable from the integrity of the conclusions. Third, that authorship is a responsibility, not just a credit line, and disputes about who did or did not contribute are treated with seriousness by editors. And finally, that single studies, especially early animal studies of natural compounds, should always be viewed as provisional. The hypothesis that acteoside might calm inflammation in arthritic joints may yet be tested rigorously by other groups with clean data. Until then, the scientific record now accurately reflects what is and is not known, and that accuracy is the foundation on which all future research depends.

Subject of Research: Retraction of a study on acteoside and the JAK/STAT inflammatory pathway in osteoarthritis due to image irregularities

Article Title: Retraction Note: Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats

Article References: Qiao, Z., Tang, J., Wu, W., Tang, J., & Liu, M. (2026). Retraction Note: Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats. BMC Complementary Medicine and Therapies, 26(1), Article 285. https://doi.org/10.1186/s12906-026-05627-5

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05627-5

Keywords: retraction, acteoside, osteoarthritis, JAK/STAT pathway, research integrity, image duplication, BMC Complementary Medicine and Therapies, authorship dispute, inflammation, natural compounds, scientific publishing, figure manipulation

L-carvone is a ketone monoterpene best known as the characteristic scent of spearmint, produced by plants of the Mentha genus. It exists as two mirror-image forms, or optical isomers, with the (R)-(−) form, known as L-carvone, and the (S)-(+) form, known as D-carvone, displaying distinct biological profiles. Previous research has attributed a remarkable range of activities to carvone, including antibacterial, antifungal, antioxidant, anti-neurodegenerative, vasorelaxant, and anticancer effects. Studies have also linked the compound to cardiovascular protection and atheroprotection through mechanisms such as reducing foam cell formation, modulating macrophage balance, and lowering oxidative stress. The new study, led by Guilherme Miniskiskosky and senior author Andréa Emilia Marques Stinghen at the Federal University of Paraná in Curitiba, is the first to test whether these properties extend to the specific inflammatory storm that uremia unleashes on blood vessel walls.

To create a realistic model of the uremic environment, the researchers recruited 14 patients with stable end-stage kidney disease undergoing hemodialysis at a single dialysis unit in Curitiba, Brazil. Participants had been on dialysis for at least three months, and the team carefully excluded anyone with active infection, cancer, autoimmune disease, liver dysfunction, severe mineral disturbances, or use of drugs such as glucocorticoids and immunosuppressants that could confound inflammatory measurements. Serum collected from all patients was pooled in equal amounts to create an averaged uremic milieu, minimizing the influence of any single patient’s biochemistry. The study was approved by the Ethics Committee of Pontifícia Universidade Católica do Paraná, and all patients provided signed informed consent.

The experimental system centered on EA.hy926 cells, a well-established human endothelial cell line, grown under standard conditions and exposed for 24 hours to one of three treatments: a 10 percent uremic serum pool, L-carvone at 100 micromolar, or the two combined. The carvone dose was chosen after a careful dose-response screen. At concentrations of 200 micromolar and above, the compound significantly reduced endothelial cell viability, but at 100 micromolar it left viability untouched, whether applied alone or alongside uremic serum. This established a safe working concentration for probing anti-inflammatory effects without cytotoxic confounders. The 24-hour exposure window was selected to allow sufficient time for transcriptional and inflammatory responses to unfold.

The results were striking. Uremic serum, as expected, drove up gene expression of the pro-inflammatory interleukins IL-6, IL-8, and IL-1β in the endothelial cells. When L-carvone was added, it significantly reduced IL-1β gene expression compared with uremic serum alone, a finding of particular importance because IL-1β sits near the top of the inflammatory cascade, amplifying vascular damage through activation of the nuclear factor kappa-B (NF-κB) pathway and contributing to arterial calcification. At the protein level, the effects broadened considerably. Carvone treatment significantly lowered production of IL-6, IL-8, and IL-1β, as well as tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor A (VEGF-A), and serum amyloid A (SAA), an acute-phase protein secreted by the liver that promotes pro-inflammatory and pro-thrombotic activity on vascular endothelial cells. Levels of the adhesion molecule ICAM-1 also fell substantially, from about 12.05 picograms per milliliter in uremic serum-treated cells to 6.25 picograms per milliliter when carvone was present.

Beyond quieting inflammatory signaling, the compound appeared to interfere with one of the most consequential steps in atherosclerosis: the recruitment of monocytes to the vessel wall. Endothelial cells exposed to uremic serum produce monocyte chemoattractant protein 1 (MCP-1), a chemical beacon that draws circulating monocytes toward the endothelium, where they can invade the vessel wall and seed atherosclerotic plaques. In the study, carvone significantly reduced MCP-1 production under uremic conditions. To test the functional consequence, the team used modified Boyden chambers, placing treated endothelial cell supernatant in the lower compartment and U-937 monocyte-like cells above a porous membrane. Supernatant from uremic serum-treated endothelial cells significantly increased monocyte migration, but supernatant from cells co-treated with carvone significantly reduced it, demonstrating that the anti-inflammatory effect translates into reduced leukocyte recruitment.

Perhaps the most visually compelling evidence came from scanning electron microscopy. Untreated control cells displayed the classic architecture of intact endothelium, spread flat across the substrate in a confluent monolayer. Cells exposed to uremic serum showed the hallmarks of uremic injury: an abundance of filopodia, loss of intercellular adhesions, rounded cell bodies, perforations in the plasma membrane, and scattered cellular debris. These morphological changes matter because uremic toxins are known to disrupt adherens and occluding junctions between endothelial cells, increasing vascular permeability and accelerating vascular damage. Remarkably, cells treated with uremic serum plus carvone largely reverted to a control-like pattern, remaining adhered and spread across the substrate. Carvone also promoted endothelial cell proliferation, which the authors suggest could support regeneration of an endothelial barrier damaged by toxin accumulation, although they caution that increased proliferation alone does not prove restored barrier function.

The authors are careful to frame these findings as mechanistic observations rather than a prescription. The 100 micromolar concentration used in vitro may exceed the circulating levels achievable in humans, since pharmacokinetic studies indicate that carvone is rapidly metabolized and cleared, and quantitative data on attainable plasma or tissue concentrations remain limited. Previous human studies have documented systemic exposure to carvone after oral intake of peppermint and caraway oil preparations and after topical exposure, but these do not establish clinical efficacy or safety of isolated carvone in CKD patients. The researchers also acknowledge that they did not directly measure NF-κB activation or antioxidant pathways, so the precise molecular mechanism behind the observed effects remains speculative, even though other experimental models have linked carvone’s anti-inflammatory actions to NF-κB inhibition.

Additional limitations shape how the results should be interpreted. The EA.hy926 cell line, while a standard tool, may not fully reproduce the behavior of primary human endothelial cells, and validation in primary cells is needed. The pooled serum from 14 patients smooths away inter-individual variability, so studies using serum from larger numbers of individual patients will be important to confirm that the effects hold across different clinical profiles. The authors also note that future work should explore carvone’s effects in other relevant cell types, such as vascular smooth muscle cells and renal tissue, and that in vivo studies will be essential to understand how the compound behaves in complex biological systems.

Even with those caveats, the study represents a genuine first. The researchers demonstrated for the first time that the dysfunctional, inflammatory profile that uremia imposes on endothelial cells can be attenuated by L-carvone treatment in vitro, with reductions in inflammatory biomarkers, reduced leukocyte recruitment, and reversal of uremia-induced structural damage. Because elevated levels of molecules like IL-6, TNF-α, and MCP-1 are linked to poorer cardiovascular prognosis, blunting their production could, in principle, translate into meaningful vascular protection for the CKD population. The work opens a new avenue for investigating how natural monoterpenes might be harnessed against uremic inflammation, and it provides a foundation for the animal studies and, eventually, clinical trials that would determine whether the spearmint molecule can move from the culture dish to the dialysis clinic.

Subject of Research: Anti-inflammatory effects of L-carvone on uremia-induced endothelial dysfunction in chronic kidney disease

Article Title: Potential anti-inflammatory effect of L-carvone in endothelial dysfunction triggered by uremia related to chronic kidney disease

Article References: Miniskiskosky, G., da Cunha, R. S., Gregório, P. C., Azevedo, C. A. B., Pereira, V. C., de Souza Ramos, E. A., & Stinghen, A. E. M. (2026). Potential anti-inflammatory effect of L-carvone in endothelial dysfunction triggered by uremia related to chronic kidney disease. Molecular Biology Reports, 53(1), Article 1651. https://doi.org/10.1007/s11033-026-12806-7

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12806-7

Keywords: chronic kidney disease, L-carvone, endothelial dysfunction, uremic toxins, inflammation, hemodialysis, monoterpene, cardiovascular disease, IL-1β, MCP-1, monocyte recruitment, natural compounds

Now, a research team led by Professor Jun Zhang from the Shihezi University School of Medicine in China, together with Professor Jingzhou Wang and Dr. Cuizhe Wang from Shihezi University, has reported findings that may reshape how scientists think about intercepting advanced prostate cancer. Their study, published in the Chinese Medical Journal and made available online on July 15, 2026, centers on a transcription factor called Krüppel-like factor 7, or KLF7, a protein that binds to DNA and regulates the expression of downstream genes. Using RNA sequencing and bioinformatics analysis of prostate cancer samples, the team discovered that KLF7 is highly expressed in prostate tumors, where it acts as a direct transcriptional activator of L1 cell adhesion molecule, known as L1CAM. This cell-surface protein has long been associated with tumor metastasis, the process by which cancer cells detach from the primary tumor, invade surrounding tissues, and colonize distant organs. By linking KLF7 to L1CAM expression, the researchers identified a previously underappreciated route through which prostate cancer cells acquire their malignant properties.

The significance of the finding deepened when the investigators traced the regulatory chain one step further upstream. Above KLF7 in the signaling hierarchy sits nuclear factor kappa B, or NF-κB, a master transcriptional regulator famous for its roles in inflammation, immunity, and cancer. Specifically, the study demonstrated that the phosphorylation of the NF-κB p65 subunit serves as the master regulator of the entire KLF7/L1CAM axis. When p65 is phosphorylated, it becomes transcriptionally active, driving KLF7 expression, which in turn switches on L1CAM and promotes the aggressive behaviors that characterize advanced prostate cancer. This three-component pathway, the NF-κB/KLF7/L1CAM axis, therefore represents a linear signaling circuit in which a single upstream event, the phosphorylation of p65, can unleash a cascade of pro-tumor effects. Interrupting that circuit at its origin could, in principle, suppress the entire malignant program with a single intervention.

That is exactly where gallic acid enters the story. Gallic acid is a naturally occurring phenolic compound found in gallnuts, tea leaves, grapes, and a variety of other plant sources, and it has attracted growing attention for its anti-inflammatory and anti-cancer properties. What remained unclear until now was the precise molecular mechanism by which it might act against prostate cancer. To resolve this question, the research team turned to two complementary structural and biophysical techniques: surface plasmon resonance and molecular docking. Surface plasmon resonance is a label-free optical method that measures real-time binding between molecules, allowing researchers to confirm whether a small molecule physically attaches to a target protein and how stable that interaction is. Molecular docking, by contrast, uses computational modeling to predict exactly where and how a ligand fits into the three-dimensional structure of its protein target.

Using these approaches, the researchers confirmed that gallic acid forms a stable complex with the NF-κB p65 subunit, and they pinpointed the interaction with remarkable precision: the compound specifically targets the serine 276 phosphorylation site of p65. This site is a critical regulatory node, because phosphorylation at serine 276 is one of the key modifications that activates p65 as a transcription factor. By occupying or otherwise interfering with this site, gallic acid prevents the phosphorylation event from occurring, effectively locking p65 in an inactive state. The downstream consequences are exactly what the signaling model predicts: with p65 silenced, KLF7 is not activated, L1CAM is not expressed, and the pro-metastatic program that depends on this axis is shut down. In effect, gallic acid functions as a molecular circuit breaker, cutting the power to the entire pathway at its source rather than trying to suppress each downstream effect individually.

The team then moved from structural biology to functional validation, testing whether this mechanism translates into meaningful effects against actual prostate cancer cells. In laboratory culture experiments, gallic acid significantly impaired the aggressive behaviors of two widely used prostate cancer cell lines, PC-3 and LNCaP. These cell lines are standard models in prostate cancer research, with PC-3 representing a highly invasive, androgen-independent phenotype and LNCaP representing an androgen-sensitive one, so activity against both suggests the compound’s mechanism operates independently of androgen signaling status. Equally important was what the researchers did not observe: gallic acid exhibited no toxicity toward normal prostate stromal cells, the healthy supporting tissue of the prostate. This selectivity profile is a critical consideration for any potential therapeutic, because many conventional cancer drugs inflict collateral damage on healthy tissue, producing the debilitating side effects that limit treatment intensity and patient quality of life.

To determine whether these cellular findings could withstand the far more demanding environment of a living organism, the researchers conducted experiments in a high-fat-diet-induced obesity mouse model. This model choice is scientifically deliberate rather than incidental. Obesity is a well-established risk factor for more aggressive prostate cancer, and the metabolic and inflammatory conditions it creates are known to activate NF-κB signaling, making it a clinically relevant setting in which to test a compound that targets this pathway. In these animals, administration of gallic acid significantly reduced both tumor volume and tumor weight, demonstrating that the compound’s anti-cancer effects extend beyond the controlled conditions of a cell culture dish into the complex biology of a whole organism.

Perhaps the most striking result of the in vivo work was the comparison with established drugs. The anti-tumor efficacy of gallic acid proved comparable to that of conventional therapeutics such as enzalutamide and bicalutamide, both of which are androgen receptor signaling inhibitors used in the clinic for advanced prostate cancer. Even more encouraging, combination therapy pairing gallic acid with these conventional agents produced enhanced therapeutic outcomes, suggesting that the natural compound could complement existing treatments rather than merely duplicating them. This kind of synergy is highly sought after in oncology, because combination regimens can improve efficacy while potentially allowing lower doses of each individual drug, thereby reducing toxicity. For patients whose tumors have progressed beyond the reach of hormone therapy alone, a well-tolerated natural product that sensitizes tumors to standard drugs could represent a meaningful addition to the therapeutic arsenal.

The implications of the study extend beyond prostate cancer itself. The NF-κB pathway is a central hub in the biology of inflammation and cancer more broadly, and KLF7 and L1CAM have been implicated in other malignancies as well. A validated strategy for disabling the NF-κB/KLF7/L1CAM axis through a small, naturally derived molecule could therefore inform therapeutic development in multiple cancer types. Moreover, the study exemplifies a modern, mechanism-first approach to drug repurposing: rather than simply observing that a compound has anti-cancer effects, the researchers identified the exact molecular target, the exact binding site, and the exact signaling consequences, building a complete mechanistic chain from molecule to phenotype. As the authors and their supporters, including funding from the Tianshan Talent Project in Xinjiang Autonomous Region and the Scientific and Technological Research Project of Xinjiang Production and Construction Corps, look toward future work, the study provides what the team describes as a strong theoretical basis for the clinical application of gallic acid as a safe and potent agent against advanced prostate cancer. Translating these findings into human therapies will require further preclinical development and eventually clinical trials, but the foundation has been laid: a common plant compound, a precisely defined molecular target, and a signaling axis whose disruption strikes at the heart of what makes advanced prostate cancer lethal.

Subject of Research: Inhibition of the NF-κB/KLF7/L1CAM signaling axis by gallic acid as a therapeutic mechanism against prostate cancer progression

Article Title: Chinese Medical Journal study reveals gallic acid inhibits prostate cancer progression via the NF-κB/KLF7/L1CAM Axis

Article References: Chinese Medical Journal study reveals gallic acid inhibits prostate cancer progression via the NF-κB/KLF7/L1CAM Axis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, gallic acid, NF-κB p65, KLF7, L1CAM, castration-resistant prostate cancer, transcription factor, surface plasmon resonance, molecular docking, enzalutamide, bicalutamide, natural compounds

Dental caries remains one of the most prevalent chronic diseases of childhood, and its true nature has been radically revised over the past two decades. Early research blamed a single villain, Streptococcus mutans, but shotgun metagenomic sequencing has since revealed that tooth decay is fundamentally a disease of microbial dysbiosis, an ecological imbalance in which acid-producing genera such as Veillonella, Bifidobacterium, Lactobacillus, and Actinomyces become enriched in carious lesions. At the functional level, the caries-associated microbiome upregulates genes for mixed-acid fermentation, while healthy mouths tend to express genes involved in antimicrobial peptide synthesis. Because caries is ultimately driven by the net metabolic output of a community rather than by any one species, interventions that can steer that community’s metabolism, rather than sterilize it, have become a major public health goal.

The research team, based at institutions including Shenzhen Futian District Maternal and Child Health Hospital and Southern University of Science and Technology, recruited eleven pediatric patients diagnosed with dental caries under strict criteria: no oral cleaning on the sampling day, no systemic disease, no antibiotics within three months, and no history of fluoride use. Saliva samples were collected with parental consent and ethical approval, then incubated at body temperature with hesperetin or naringenin for twenty-four hours. The researchers then extracted total DNA using a magnetic bead-based kit and performed shotgun metagenomic sequencing on the DNBSEQ-T7 platform, generating high-quality data with Q20 percentages above ninety-eight percent and Q30 values predominantly above ninety-four percent.

The bioinformatics pipeline was exhaustive. Raw reads were trimmed and filtered with Trimmomatic, host sequences were removed with KneadData, and de novo assembly was performed with MEGAHIT. Gene prediction used Prodigal, and non-redundant gene catalogs were constructed with CD-HIT, yielding more than 853,000 sequences for one sample group and more than 626,000 for another. Functional annotation was carried out against seven databases, including GO for broad functional categories, KEGG for metabolic pathways, EggNOG for orthologous groups, CAZy for carbohydrate-active enzymes, CARD for antibiotic resistance, and VFDB for virulence factors. Taxonomic assignment relied on DIAMOND alignment followed by lowest common ancestor classification in MEGAN. Reads mapping rates exceeded ninety percent for most samples, confirming that the assembled contigs reliably represented the dominant fraction of each sequenced community.

The headline result was the sheer scale of the perturbation. Across all eleven sample groups, roughly two in five annotated genes changed in abundance by more than seventy percent following flavonoid exposure. In most groups, hesperetin affected a numerically larger share of genes than naringenin, for example forty-three percent versus thirty-nine percent in one sample and forty-two percent versus thirty-nine percent in another, hinting that hesperetin may exert the broader genomic footprint. The authors are careful, however, to frame this as a descriptive observation rather than proof of intrinsically different potency, given the small cohort and the absence of formal statistical testing. What matters conceptually is that a natural compound, at a single physiologically relevant concentration, engaged the microbial community at a systems level.

Among the most biologically significant findings were shifts in the carbohydrate-active enzyme landscape. Glycosyltransferases, which build the extracellular polysaccharides of dental biofilm, and glycoside hydrolases, which break down dietary sugars, showed increased relative abundance in multiple hesperetin-treated samples. This aligns with the known role of flavonoids as modulators of carbohydrate metabolism and biofilm matrix synthesis in oral streptococci. The researchers caution that metagenomic sequencing measures gene abundance, not transcriptional activity, so whether enzymatic output actually changed remains an open question requiring metatranscriptomic or metabolomic follow-up. KEGG and EggNOG annotations likewise revealed treatment-associated shifts in metabolic pathway representation, a perspective the authors consider critical because a taxonomic shift is only clinically meaningful insofar as it alters the community’s net metabolic behavior.

Perhaps the most intriguing observation emerged from the beta diversity analyses. Principal component analysis after centered log-ratio transformation, principal coordinate analysis based on Bray-Curtis and Binary-Jaccard distances, and non-metric multidimensional scaling all showed that hesperetin-treated and naringenin-treated samples occupied distinct regions of compositional space, both taxonomically and functionally. On the functional axis, the first principal component explained between 50.74 and 61.11 percent of the variance, and NMDS stress values as low as 0.0653 confirmed reliable ordinations. The two flavonoids differ chemically by only a single hydroxyl group, yet they appeared to push the microbiome in subtly different ecological directions, a structure-activity relationship the authors plan to make the centerpiece of their follow-up mechanistic work.

Crucially, the restructuring did not resemble a scorched-earth antibiotic effect. Bacteria remained dominant in all samples, and the Shannon diversity index showed bidirectional, sample-specific changes, decreasing in one child’s community upon flavonoid exposure while increasing in another’s. This preservation of overall richness, combined with clear separation in beta diversity space, suggests the compounds may selectively restructure the community, potentially suppressing cariogenic taxa or disrupting the synergistic metabolic networks that drive enamel demineralization while sparing health-associated commensals. The authors stress that this interpretation remains speculative, but the ecological selectivity is precisely what caries prevention demands, since the goal is to restore microbial homeostasis rather than sterilize the oral cavity.

The pediatric focus adds public health weight to the findings. The developing oral microbiome of children is a dynamic, malleable ecosystem, and early childhood caries is increasingly recognized as a sentinel event that predicts long-term oral health trajectories and has been linked to systemic conditions including malnutrition, growth impairment, and poor academic performance. If dietary flavonoids can be shown in controlled studies to guide the developing microbiome toward a health-associated state, whether through dietary enrichment, functional foods, or topical formulations, the implications for early-life prevention could be substantial. The authors explicitly note that no gut microbiota data were generated, so no conclusions about the gut can be drawn from this work.

The limitations are equally clear and the authors enumerate them candidly. Eleven subjects cannot capture the enormous inter-individual variability of the oral microbiome, the ex vivo batch-culture system cannot reproduce salivary flow, diet, host immunity, or mature three-dimensional biofilm architecture, and a single concentration at a single time point precludes any statement about dose-response or temporal dynamics. Ex vivo incubation may also stochastically lose or retain low-abundance taxa, potentially confounding the observed shifts, and strain-level resolution for key cariogenic species was not achieved. The team frames the entire study as hypothesis-generating, with raw sequencing data deposited in the NCBI Sequence Read Archive under BioProject PRJNA1379526 to serve as a metagenomic baseline. Even within those constraints, the message is striking: hesperetin and naringenin, the everyday polyphenols of oranges and grapefruits, are not nutritionally passive. Under laboratory conditions they behave as ecological modulators, capable of broadly remodeling the taxonomic and functional architecture of the caries-associated oral metagenome, and they may represent the opening chapter of a genuinely ecological approach to preventing the world’s most common chronic childhood disease.

Subject of Research: Metagenomic analysis of the effects of the citrus flavonoids hesperetin and naringenin on the oral microbiome of children with dental caries

Article Title: Citrus flavonoids hesperetin and naringenin remodel the caries-associated oral microbiome: An exploratory metagenomic study

Article References: Zhu, L., Zhu, Y., Zhang, Z., Hu, S., Li, X., Zhou, Y., Shi, Z., Huang, D., Huang, R., Liu, Z., Wang, Y., Ma, F., & Tang, B. (2026). Citrus flavonoids hesperetin and naringenin remodel the caries-associated oral microbiome: An exploratory metagenomic study. Journal of Agriculture and Food Research, 31, Article 103320. https://doi.org/10.1016/j.jafr.2026.103320

Image Credits: AI Generated

DOI: 10.1016/j.jafr.2026.103320

Keywords: dental caries, oral microbiome, hesperetin, naringenin, citrus flavonoids, metagenomics, pediatric health, microbial dysbiosis, carbohydrate-active enzymes, beta diversity, natural compounds, biofilm

Tendon-bone insertion injuries, which occur where soft tendon tissue anchors into hard bone, are among the most frequently encountered injuries in daily life and sports. Their clinical burden is growing annually, and restoring normal physiological function remains remarkably difficult. The reason lies in the anatomy: the tendon-bone junction is a graded transition zone that includes a specialized fibrocartilage layer, and unlike many tissues, it cannot regenerate itself faithfully after injury. Instead, the body fills the gap with disorganized scar tissue that has low biomechanical strength. That weakness translates directly into high postoperative re-rupture rates, making rapid, high-quality regeneration an urgent challenge in orthopedics, sports medicine, and tissue engineering.

The quality of tendon-bone healing depends heavily on how well the fibrocartilage layer regenerates at the interface, and macrophages, the versatile immune cells that flood any wound site, orchestrate much of that process. In the early phase of healing, M1-polarized macrophages dominate, secreting pro-inflammatory factors such as IL-1β and IL-6 that intensify local inflammation and recruit fibroblasts to the damaged site. Later, macrophages shift toward the M2 phenotype, releasing anti-inflammatory signals like IL-10 and Arg1 that dampen inflammation and promote tissue reconstruction. Previous work has shown that this transition from a pro-inflammatory to an anti-inflammatory microenvironment is crucial for moving from the inflammatory phase into the proliferative phase of repair, and that biologically inducing early M2 aggregation at the interface actively improves healing outcomes.

What makes the new study distinctive is its focus on macrophage metabolism. M2 macrophages rely on oxidative phosphorylation and fatty acid oxidation (FAO) for their energy supply, whereas activation of PPAR signaling and its regulatory genes increases FAO capacity. The research team, led by Xiaojun Ma and colleagues, hypothesized that if a compound could push macrophage metabolism toward FAO and oxidative phosphorylation, it would favor M2 polarization and thereby improve tendon-bone healing. Didymin was a natural candidate: earlier reports had documented its purgative, anti-inflammatory, and antioxidant properties, and prior metabolic tracing experiments had revealed that the compound enhances FAO rather than glycolysis. Crucially, didymin had already been shown to modulate the M1/M2 balance by converting pro-inflammatory M1-like macrophages into anti-inflammatory M2-like ones, without altering baseline M2 polarization.

To test the hypothesis, the researchers established a mouse model of tendon-bone healing by surgically severing the Achilles tendon near the calcaneal bone, scraping away the residual fibrocartilaginous layer, drilling a bone channel, and suturing the tendon stump back to the bone, a procedure that mimics the changes seen after rotator cuff reconstruction. Thirty-six male C57BL/6J mice were randomly assigned to six groups: a sham-operated control, an untreated model group, three didymin dose groups receiving 1, 2, or 4 milligrams per kilogram per day by oral gavage, and a positive-control group receiving the drug disulfiram at 50 milligrams per kilogram per day. Treatment began one day after surgery and continued daily for four weeks, with all protocols approved by the animal ethics committee of the People’s Hospital of Ningxia Hui Autonomous Region.

The structural results were striking. Micro-computed tomography scanning showed that high-dose didymin produced new bone volume at the interface comparable to that seen in the positive-control group, with significant increases in bone volume fraction, bone surface, trabecular number, and bone mineral density, along with significantly reduced trabecular separation compared with the untreated model group. Histological staining revealed that model-group animals suffered from disorganized collagen fibers, consolidated fibroblast nuclei, necrotic areas, and inflammatory cell infiltration at the junction, all of which were attenuated by didymin treatment. Serum biochemistry told a matching story: levels of osteocalcin, alkaline phosphatase, and calcium, all markers of bone formation activity, rose significantly in the treated animals.

Fibrocartilage regeneration, the critical determinant of healing quality, also improved. Safranin-O/fast green staining showed localized absence of the cartilage layer and abnormal chondrocyte proliferation in untreated mice, defects that didymin largely corrected. Immunofluorescence assays demonstrated that expression of the cartilage markers Sox9 and Collagen II, which dropped sharply at the injured interface, was significantly restored by the compound. The researchers also measured increased expression of TGF-β1 and TGF-β3, growth factors known to drive chondrogenesis and fibrocartilage formation, further supporting the conclusion that didymin actively promotes regeneration of the specialized transition tissue rather than merely reducing inflammation.

Flow cytometry and molecular profiling of the healing tissue revealed the immune mechanism at work. Untreated model mice showed elevated levels of F4/80-positive CD86-positive M1 macrophages and elevated IL-1β and IL-6 mRNA, while didymin administration at all three doses reduced these pro-inflammatory indicators. Medium and high doses simultaneously raised the abundance of F4/80-positive CD206-positive M2 macrophages and increased expression of Arg1 and IL-10. In parallel cell experiments using bone marrow-derived macrophages, didymin significantly reduced CD86 expression under M1-polarizing conditions and boosted levels of acetyl-CoA, the FAO enzymes Cpt1a and ACS, and the PPAR pathway proteins PPAR-γ and RXRA, indicating a metabolic reprogramming toward fatty acid oxidation.

The team then ran a decisive validation experiment using pharmacological blockers. When the PPAR-γ antagonist GW9662 or the fatty acid oxidation inhibitor etomoxir was added to didymin-treated M1 macrophages, the compound’s effects were substantially reversed: acetyl-CoA levels, CD206-positive M2 populations, and anti-inflammatory Arg1 and IL-10 expression all fell, while CD86-positive M1 populations and pro-inflammatory IL-1β and IL-6 rose again. This loss-of-function evidence strongly suggests that didymin drives macrophage polarization toward the M2 phenotype specifically by promoting the PPAR signaling-mediated FAO pathway, which in turn supports tendon-bone healing.

The authors acknowledge important limitations that temper immediate clinical translation. No biomechanical testing was performed, the antagonist and inhibitor experiments were conducted only in cell culture rather than in living animals, and all mice received local penicillin injections postoperatively, which could theoretically interact with didymin’s anti-inflammatory and antibacterial properties. Only male mice were studied, and sex is known to influence inflammatory responses, bone metabolism, and tendon healing, so verification in female animals is needed. The mouse Achilles model also cannot fully reproduce the biomechanics, vascular supply, and stress conditions of human rotator cuff attachment sites. Even so, the study lays a concrete foundation for didymin as a candidate therapy, linking a dietary flavonoid, immune cell metabolism, and musculoskeletal regeneration in a single mechanistic chain that future research can now build upon.

Subject of Research: The role of didymin in promoting tendon-bone healing through PPAR-mediated fatty acid oxidation and macrophage M2 polarization

Article Title: Didymin may Enhance Tendon‐Bone Healing Partly by Promoting PPAR‐Mediated Fatty Acid Oxidation and Macrophage M2 Polarization

Article References: Ma, X., Shen, J., Ma, J., Li, H., Li, Y., & Wan, J. (2026). Didymin may Enhance Tendon‐Bone Healing Partly by Promoting PPAR‐Mediated Fatty Acid Oxidation and Macrophage M2 Polarization. Immunity, Inflammation and Disease, 14(9), Article e70485. https://doi.org/10.1002/iid3.70485

Image Credits: AI Generated

DOI: 10.1002/iid3.70485

Keywords: didymin, tendon-bone healing, macrophage polarization, M2 macrophages, PPAR signaling, fatty acid oxidation, fibrocartilage, Achilles tendon, rotator cuff, bone regeneration, inflammation, natural compounds